Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood (PB) is increasingly selected as a source of stem cells for allogeneic transplantation. 1 The shift from using bone marrow (BM) to PB stem cells is based on the faster haematological recovery and lower transplant-related mortality (TRM) in patients with advanced disease observed after transplantation with PB. 2 However, it remains unclear whether the use of PB is associated with an increased incidence of acute graft-versus-host disease (GvHD). Several retrospective and randomized prospective studies comparing BM and PB found a similar incidence of acute GvHD, 2, 3 except the European Group for Blood and Marrow Transplantation (EBMT) study, which seems to indicate that PB transplants are associated with an increased cumulative incidence of acute GvHD. 4 This association was recently confirmed by a meta-analysis of nine randomized trials. 5 Nevertheless, it seems clear that PB transplants have an increased risk of chronic GvHD. [2] [3] [4] [5] Many genes located on the Y-chromosome have been reported to encode male-specific minor histocompatibility antigens (mHags) (SMCY, DFFRY, UTY, DBY), and cytotoxic T-lymphocytes directed against these mHAgs have been found in patients with acute GvHD or graft rejection. 6 In fact, many studies have identified the combination male recipient/female donor as a risk factor for both acute and chronic GvHD after human lymphocyte antigen (HLA)-identical sibling donor allogeneic transplantation. Moreover, recipients of HLA-identical but sex-mismatched grafts have higher TRM and a poorer transplantation outcome than those who receive a graft matched for sex. 7 However, most of these studies analysed patients receiving BM as a stem cell source.
Our study aim to define whether the presence of a sex mismatch should also be considered a pre-transplant risk factor in the case of PB transplantation. To avoid confusing factors, the analysis was restricted to 629 patients with acute leukaemia, chronic myeloid leukaemia (CML) or myelodysplastic syndrome (MDS) receiving an allogeneic transplant from an HLA-identical sibling donor without T-cell depletion between 1995 and 2005. All patients were given a myeloablative therapy, which consisted of cyclophosphamide and total body irradiation or busulphan þ cyclophosphamide. Prophylaxis of GvHD was cyclosporin A and short-term methotrexate for all patients. The stem cell source was BM for 267 patients and G-CSF-mobilized PB in 362 cases. The transplant dates were comparable between PB and BM transplants. The presence of a sex mismatch was documented in 155 patients (81 receiving PB and 74 transplanted with BM). Patients' characteristics are listed in Table 1 . The cohort of patients receiving PB had more cases with advanced disease. However, the aim of this study was not to compare the clinical outcome after PB or BM transplantation, but the relevance of the presence of a sex mismatch depending on the stem cell source. Homogeneity between patients receiving a sex-mismatched allograft and the non-mismatched pairs was confirmed. Two cohorts (BM and PB transplants) were analysed separately. The follow-up was stopped 7 years after transplant. Median observation time of surviving patients was 3.9 years (range: 5-84 months).
Sex mismatch was associated with an increased risk of severe (grades III-IV) GvHD in the univariate analysis for those patients transplanted with BM (20 vs 7%; P : 0.007). However, for patients receiving PB we did not find any statistical association between sex mismatch and severe acute GvHD (28 vs 21%; P : 0.300). Multivariate analysis identified the presence of sex mismatch as an independent risk factor for grade III-IV GvHD for patients receiving BM as a stem cell source (P: 0.018; relative risk (RR): 2.68; 95% confidence interval (CI): 1.18-6.09), but not for those receiving PB (P: 0.529). The presence of a sex mismatch did not influence the cumulative incidence of grade II-IV acute GvHD in either BMor PB-transplanted patients. Figure 1 shows the cumulative incidence of grade III-IV acute GvHD depending on the presence of a sex mismatch in both cohorts (BM and PB). As reported previously, extensive chronic GvHD was more frequent in PB-transplanted patients (32.7 vs 20.3%; P: 0.002). For these patients, the incidence of extensive chronic GvHD was higher in the presence of a sex mismatch (45.6 vs 29.6%; P: 0.024). The multivariate analysis confirmed this association (P: 0.042; RR: 1.96; 95% CI: 1.02-3.76). In contrast, the presence of a sex mismatch did not affect the extensive chronic GvHD incidence (25.5 vs 18.7%; P: 0.290) in the BM-transplanted group.
Cumulative incidence of TRM was 40 and 18% for patients receiving BM with and without sex mismatch, respectively (Po0.001). This association of sex mismatch and TRM was confirmed in the multivariate analysis (Po0.001; RR: 2.98; 95% CI: 1.76-5.06). However, TRM did not increase in patients receiving PB with sex mismatch (39 vs 30%; P: 0.222). The multivariate analysis also failed to detect any statistical significance. Figure 2 shows the incidence of TRM associated with the presence or absence of a sex mismatch based on the stem cell source.
Sex-mismatched patients receiving BM as a source of stem cells had significantly poorer survival than those receiving BM without mismatch (41.4 vs 68.3%; Po0.001). However, overall survival was not affected by the presence of a sex mismatch in patients transplanted with PB (41.4 vs 48.3%; P: 0.155) (Figure 3 ). Multivariate analysis confirmed the negative effect of the sex mismatch on overall survival for patients receiving BM (Po0.001; RR: 2.29; 95% CI: 1.49-3.51). In a detailed analysis of only 204 patients with CML, we detected the same effect as that observed for patients with acute leukaemia: sex mismatch was associated with worse survival for patients receiving BM (55.5 vs 78.9%; P: 0.026) but not for those receiving PB (46.3 vs 50.1%; P: 0.551).
Male patients receiving PB stem cells from a female donor had the same incidence of grade III-IV acute GvHD as those transplanted with BM (31.2 vs 25.9%; P: 0.383), but they had more extensive chronic GvHD (45.6 vs 25.5%; P: 0.030). Overall survival, however, was not statistically different (41.4 vs 41.4%; P: 0.595). However, patients without sex mismatch transplanted with PB had a higher incidence of grade III-IV acute GvHD (22.7 vs 11.1%; P: 0.003) and extensive chronic Cumulative incidence of TRM depending on the presence of a sex mismatch after PB transplantation (a) or BM transplantation (b).
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GvHD (29.6 vs 18.7%; P: 0.016) than those receiving BM. Overall survival was better in the BM group (PB: 48.3 vs BM: 68.3%; P: 0.003). Nevertheless, the comparison between PB and BM was affected by a greater presence of cases with advanced disease in the PB group for patients without sex mismatch. When considering only those patients with early disease (n: 302), we detected the same differences in acute and chronic GvHD, but overall survival was similar (PB: 64.4 vs BM: 72.4%; P: 0.259).
The combination female donor/male recipient has been traditionally described as a risk factor for GvHD, as well as for TRM after BM transplantation, but there are not enough studies to confirm whether this risk factor should be applied to PB allogeneic transplants. Our findings confirmed the association of a sex mismatch and severe acute GvHD, higher TRM and lower overall survival after BM transplantation from an HLA-identical sibling donor, but we did not find the same results after PB allogeneic transplantation. One possible explanation for these differences may be the different cell composition of unmanipulated PB and BM allografts. Indeed, the total numbers of T cells, monocytes and natural killer cells contained in a PB allograft are more than 10 times higher than in a BM allograft. In contrast, BM is rich in accessory cells, which are co-transplanted with haematopoietic stem cells. These accessory cells include fat and endothelial cells, as well as mesenchymal stem cells and T-regulatory (CD4 þ CD25 þ ) cells. The presence of these cells in the BM allograft could be associated with increased tolerance to non-dominant mHags. In other words, T-lymphocytes transplanted with PB may recognize more antigen mismatches than cells derived from a BM allograft, leading to an alloreactive response even in the absence of immunodominant mismatches, such as the H-Y mismatch. This would explain why PB transplants have a similar acute GvHD and TRM incidence, independently of whether a sex mismatch is present.
Overall survival is affected by the presence of an H-Y mismatch after BM (but not PB) transplantation. This observation is relevant because many studies take patients receiving BM and PB together when analysing risk factors for clinical outcome after allogeneic stem cell transplantation. The EBMT study of risk assessment for patients with CML based on a scoring system included the presence of a sex mismatch (male recipient and female donor) as one of the items to be considered when the score is assigned to the patient, but the study examined patients receiving BM and PB as a stem cell source together. 8 When we analysed CML patients separately, we also found that sex mismatch was associated with worse survival after BM transplants but not when PB was used as a stem cell source. These results suggest that many studies on risk factors for clinical outcome need to be redefined on the basis of their stem cell source. Overall survival depending on the presence of a sex mismatch after PB transplantation (a) or BM transplantation (b). 

